Mengyao Li

Mengyao Li

Auto-generated profile, based on publicly available information

Mengyao Li

Technical Research and Development, Novartis Pharma AG

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2023 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
APAleksandr Pogodaev
Aleksandr Pogodaev
TRTanja Hernández Rodríguez
Tanja Hernández Rodríguez
MLMengyao Li
Mengyao Li
DMDavid Gerardo García Münzer
David Gerardo García Münzer

28 January 2026 in Industrial & Engineering Chemistry Research
Verified
Journal Article
Closed access
DRDiego Balthasar Renner
Diego Balthasar Renner
MLMengyao Li
Mengyao Li
JAJoao Alcantara
Joao Alcantara
NCNuno Buxo Carinhas
Nuno Buxo Carinhas
DGDavid Garcia
David Garcia

24 June 2026 in Applied Spectroscopy Practica
Verified
Journal Article
Open access
JAJoão Medeiros Garcia Alcântara
João Medeiros Garcia Alcântara
BFBoris Fessler
Boris Fessler
APAriana Peredo
Ariana Peredo
MLMengyao Li
Mengyao Li
NZNiklas Zell
Niklas Zell
DGDavid Garcia
David Garcia
In biopharmaceutical production, ultrafiltration and diafiltration (UF/DF) becomes essential when high concentrations and tight control over the final formulation of drug substance is needed. Currently, the possibilities for direct inline monitoring of this process step are limited. This study evaluates the effectiveness of three spectroscopic techniques, i.e., mid-infrared (MIR), Raman, and variable pathlength ultraviolet (UV), for inline monitoring of protein concentration. Results demonstrate that all three techniques are suitable for monitoring this operation, with root mean squared errors of prediction (RMSEP) of 5.0, 3.2, and 3.2% for MIR, variable pathlength UV, and Raman spectroscopy, respectively. MIR and Raman spectroscopy were also tested for the quantification of excipient concentration in solution, with promising results. These findings indicate that all these advanced spectroscopic methods can enable inline monitoring capabilities, thus reducing the reliance on time-consuming offline analytics and leading to shorter development timelines. This integration of process analytical technology (PAT) tools in biopharmaceutical manufacturing can offer potential improvements in process control and variability reduction.